Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||DS-1205c + Osimertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DS-1205c||DS 1205c|DS1205c||AXL Inhibitor 27||DS-1205c is a small molecule inhibitor of Axl, which may have anti-tumor activity (J Thorac Oncol. 2017 Nov, 12(11): S2289-S2290, abstract P3.04-012).|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 20||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions, L858R, or T790M (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03255083||Phase I||DS-1205c + Osimertinib||DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer||Active, not recruiting|